vaccin
base
viruslik
particl
prove
success
human
health
year
approv
first
vaccin
base
technolog
substanti
effort
expand
rang
applic
target
diseas
begin
bear
fruit
incurs
highthroughput
screen
technolog
combin
new
develop
protein
engin
chemic
coupl
acceler
develop
system
capabl
produc
macrostructur
use
vaccinolog
gene
deliveri
immunotherapi
bionanotechnolog
review
summar
recent
develop
microbi
cell
factori
cellfre
system
viruslik
particl
product
discuss
futur
impact
technolog
human
anim
health
biopharmaceut
protein
wide
use
treatment
cancer
diabet
chronic
viral
hepat
inflammatori
autoimmun
diseas
number
biopharmaceut
market
product
system
base
mammalian
cell
escherichia
coli
remain
workhors
biopharmaceut
product
product
platform
select
base
complex
e
coli
express
prefer
small
protein
nonposttransl
modif
need
produc
meanwhil
chines
hamster
ovari
cho
cell
line
prefer
larger
protein
posttransl
modif
product
recent
advanc
metabol
engin
system
biolog
highthroughput
screen
approach
ad
new
develop
heterolog
protein
product
improv
limit
product
system
mainli
bacteria
yeast
overcom
use
synthet
biolog
engin
microorgan
perform
complic
posttransl
modif
includ
better
disulfid
bond
format
first
step
glycosyl
e
coli
highli
enhanc
secret
yeast
glycosyl
protein
product
therapeut
use
human
yeast
discuss
elsewher
issu
moreov
preconcept
therapeut
protein
product
chang
incurs
new
technolog
includ
cellfre
protein
synthesi
cfp
system
made
possibl
costeffect
manufactur
scale
synthesi
complex
protein
within
group
biopharmaceut
next
gener
vaccin
play
import
role
global
health
genom
system
biolog
contribut
enorm
understand
human
immunolog
ad
knowledg
result
new
technolog
may
reach
market
soon
new
vaccin
base
viruslik
particl
repres
advanc
develop
safer
vaccin
less
side
effect
improv
immunogen
review
focu
viruslik
particl
product
microbi
factori
cellfre
system
futur
therapeut
technolog
vaccinolog
gene
deliveri
system
viruslik
particl
vlp
multisubunit
protein
complex
capabl
selfassembl
form
structur
mimic
conform
nativ
virus
lack
viral
genet
materi
make
noninfecti
unabl
replic
consid
safer
tradit
vaccin
base
attenu
inactiv
virus
revers
attenu
vaccin
strain
potenti
incomplet
inactiv
viru
avoid
vlp
excel
candid
vaccin
repetit
array
surfac
recogn
immun
system
induc
strong
humor
cellular
respons
first
activ
b
cellmedi
immun
respons
produc
high
titer
neutral
antibodi
secondli
induc
strong
specif
cytotox
lymphocyt
ctl
respons
absenc
adjuv
three
decad
research
vlp
product
emerg
promis
technolog
vaccinolog
gene
deliveri
sourc
nanomateri
recent
review
reveal
vlp
differ
famili
avail
onlin
wwwsciencedirectcom
construct
evalu
differ
field
highlight
versatil
increas
scientif
interest
figur
summar
differ
platform
avail
use
produc
differ
vlp
configur
first
recombin
vaccin
hepat
viru
hbv
approv
food
drug
administr
fda
recombivax
hb
merck
co
inc
vlpbase
vaccin
produc
baker
yeast
saccharomyc
cerevisia
nowaday
sever
version
vaccin
produc
differ
biopharmaceut
compani
around
world
result
incorpor
vaccin
infant
childhood
immun
schedul
decreas
hbv
infect
preval
worldwid
achiev
recent
two
approv
human
papillomaviru
hpv
vaccin
gardasil
merck
co
inc
cervarix
glaxosmithklin
demonstr
high
protect
main
highrisk
hpv
infect
gardasil
produc
cerevisia
approv
fda
meanwhil
cervarix
produc
insect
cellsbaculoviru
system
icbv
approv
fda
vaccin
protect
two
hpv
type
caus
cervic
cancer
vagin
cancer
anal
cancer
vulvar
cancer
gardasil
also
protect
two
hpv
type
provok
genit
wart
decemb
china
state
food
drug
administr
sfda
approv
hecolin
xiamen
innovax
biotech
first
hepat
e
vaccin
base
recombin
vlp
capsid
protein
viru
vaccin
produc
e
coli
demonstr
efficaci
three
dose
vlpbase
vaccin
candid
human
health
clinic
trial
influenza
sponsor
novavax
medicago
norwalk
viru
ligocyt
pharmaceut
skin
cancer
allerg
asthma
cyto
biotechnolog
malaria
glaxosmithklin
chikungunya
viru
nation
institut
allergi
infecti
diseas
figur
show
distribut
clinic
trial
current
underway
base
number
open
studi
wwwclinicaltrialsgov
anim
vaccinolog
ingelvac
circoflex
circumv
pcv
two
porcin
circoviru
type
vlpbase
vaccin
develop
boehring
ingelheim
intervet
respect
produc
icbv
commerci
avail
us
market
sinc
new
develop
treatment
zoonot
diseas
dengu
nipah
viru
bovin
rotaviru
sar
coronaviru
calciviru
among
other
differ
stage
develop
preclin
trial
chemic
genet
modif
outer
surfac
inner
caviti
vlp
facilit
develop
new
materi
could
meet
requir
drug
deliveri
biocompat
solubl
uptak
effici
microbi
factori
prefer
product
host
simplic
higher
yield
bacteriophagederiv
vlp
common
strategi
qb
vlp
produc
e
coli
use
deliv
rnabas
dnabas
drug
also
encapsul
differ
molecular
cargo
transport
divers
cell
type
eg
quantum
dot
chemotherapi
drug
protein
toxin
bacteriophag
capsid
express
e
coli
pharmaceut
biotechnolog
multilay
use
enzym
deliveri
scaffold
magnet
reson
imag
mri
contrast
agent
yeastbas
express
system
use
produc
cowpea
chlorot
mottl
viru
ccmv
capsid
vlp
properti
ccmv
capsid
vlp
vlp
effici
captur
packag
neg
charg
speci
chimer
vlp
product
use
microbi
cell
factori
vaccin
antigen
abl
selfassembl
incorpor
wellcharacter
vlp
structur
either
genet
clone
specif
region
capsid
protein
gene
chemic
coupl
use
differ
chemistri
strategi
particl
call
chimer
vlp
present
foreign
epitop
surfac
vlp
effect
strategi
vaccin
design
microorgan
inexpens
platform
develop
standard
process
multipl
epitop
candid
product
chimer
vlp
use
hbv
core
protein
hbc
use
e
coli
yeast
prefer
express
platform
year
hbc
highli
immunogen
protein
elicit
strong
bcell
tcell
respons
particl
allow
genet
insert
wide
varieti
foreign
antigen
bacteria
virus
protozoa
specif
sequenc
tumor
inhibit
hbc
also
contain
approxim
cystein
residu
surfac
core
particl
react
alkyl
agent
allow
chemic
coupl
extern
peptid
promis
hbcvlpbase
vaccin
clinic
trial
malaria
influenza
also
test
sirna
carrier
take
advantag
unspecif
deliveri
oligonucleotid
via
clathrinmedi
endocytosi
pathway
exampl
chimer
platform
express
microbi
factori
includ
anim
polyomaviru
capsid
protein
vlp
express
cerevisia
e
coli
capabl
harbor
aa
epitop
certain
site
chimer
hepat
e
vlp
oral
deliveri
recombin
coat
protein
vlp
express
e
coli
modifi
chemic
coupl
produc
vlp
vivo
suffer
difficult
control
environ
vlp
toxic
prevent
adequ
cell
growth
creat
vlp
nonnatur
amino
acid
nnaa
cellfre
product
system
attract
platform
vlp
alreadi
success
produc
e
coli
yeast
cellfre
extract
vlp
contain
toxic
intermedi
protein
nnaa
success
produc
cellfre
extract
microbi
cell
factori
cellfre
system
offer
two
distinct
advantag
vlp
product
commerci
versatil
scalabl
vlp
flexibl
platform
rapid
respons
emerg
pathogen
diseas
outbreak
pandem
consid
chimer
vlp
easili
conjug
epitop
tune
chemistri
immunogen
inform
human
anim
immunolog
avail
vlp
engin
differ
epitop
adjuv
affect
immun
respons
differ
decreas
secondari
effect
reduc
number
dose
requir
immun
librari
specif
vlp
eg
hbc
differ
peptid
conjug
alkyn
chemistri
could
creat
immunogen
would
assay
use
highthroughput
technolog
acceler
discoveri
new
vaccin
candid
inde
vaccin
candid
treatment
hypertens
alzheim
diabet
asthma
osteoporosi
test
could
use
clinic
near
futur
hand
cellfre
system
base
microbi
cell
attract
platform
necessari
incorpor
nnaa
howev
cellfre
system
product
take
chemistri
need
avail
produc
complex
vlp
recent
disulfid
bond
format
success
shown
cellfre
system
howev
creat
complic
posttransl
modif
vitro
compartment
still
need
scalabl
issu
occur
vlp
technolog
biopharmaceut
product
microbi
cell
factori
highli
advantag
platform
vlp
product
allow
scale
process
high
product
minimum
nutrit
requir
true
microbi
system
disadvantag
compar
mammalian
cell
line
protein
product
viruslik
particl
futur
microbi
factori
cellfre
system
platform
vaccin
develop
sekar
tyo
posttransl
modif
proper
fold
immunogen
certain
compon
etc
new
develop
metabol
engin
improv
versatil
microbi
system
develop
therapeut
protein
anim
human
use
cellfre
system
continu
scale
becom
entic
platform
vlp
product
abil
control
environ
ph
concentr
ion
mean
potenti
higher
titer
vlp
compar
vivo
system
demonstr
cellfre
system
scale
show
promis
larger
scale
near
futur
cellfre
product
continu
increas
becom
viabl
option
interest
approach
improv
human
health
control
zoonot
diseas
anim
avoid
transmiss
human
farm
companion
anim
soon
vaccin
vlpbase
product
prefer
vlp
product
platform
allow
better
profit
margin
employ
interchang
product
strategi
use
microbi
vlp
product
veterinari
vaccin
reach
profit
margin
similar
tradit
inactiv
veterinari
vaccin
also
immun
respons
anim
could
coadjuv
use
cellular
compon
bacteria
yeast
lipopolysaccharid
yeast
cell
wall
allow
stronger
immun
respons
lower
dose
per
anim
drastic
decreas
product
cost
vlp
produc
microbi
factori
could
make
vaccin
neglect
tropic
diseas
sustain
busi
model
despit
low
product
price
intern
nonprofit
organ
invest
vaccin
technolog
capabl
deliv
lowcost
solut
commun
need
conclus
microbi
factori
cellfre
system
platform
allow
produc
vlp
costeffect
manner
competit
advantag
use
interchang
technolog
scope
technolog
reflect
vaccin
develop
also
gene
therapi
diagnost
biomedicin
